Delos Capital — 2023 Investments
3 investments dated 2023 · listed companies and verified rows first · show all
Eccogene is a clinical-stage biopharmaceutical company developing oral small molecule therapeutics for cardiometabolic and inflammatory conditions, including obesity, type 2 diabetes, and liver disease.
BiotechHealthtechCambridge, US
Jingye Zhou(Founder)in
Co-investorsNew Alliance Capital
Ensoma is a genomic medicine company developing a platform for in vivo engineering of hematopoietic stem cells (HSCs), combining an off-the-shelf delivery system with a gene engineering toolkit intended to treat diseases with a one-time treatment.
BiotechHealthtechMedical DevicesBoston, US
Albert Seymour(Director)
BoardKush Parmar(Executive Officer, Director)inPaula Soteropoulos(Director)Stephen Knight(Director)in
Co-investors5AM VenturesAju IB Invesment CorporationCatalio Capital Management, LPF-Prime CapitalSolasta VenturesAlexandria+7 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.